At AD/PD, researchers reported that low-intensity electric current sent through the brain at gamma frequency restored cholinergic transmission and boosted short-term memory.
Data from France and Germany bolster the proposed link between herpes virus and Alzheimer’s. Infection upped risk in ApoE4 carriers, damaged brain tissue, and correlated with neurodegeneration markers in the CSF.
Disruption of the membraneless organelles may explain toxicity of tau aggregates.
In cell culture, neurons with the strongest expression of cell-cycle proteins survived best in the presence of Aβ oligomers, hinting at a protective effect.
Based on early stage trials, scientists at AD/PD said that light and sound can promote neuronal communication, calm immune cells, and slow brain atrophy. On cognitive outcomes, the jury is still out.
After news on “new data” they won’t see, three committee members penned an editorial laying out their argument against approval. The agency is expected to decide on the licensing application by June.
In therapy-like paradigm, suppressing ApoE4 in astrocytes toned down tauopathy. This assuaged microglia, neurodegeneration, and revived nest-building.
New research implicates IL-6 signaling and even Aβ42 itself as BACE targets, complicating efforts to resurrect BACE inhibitors at a low dose.
Data from Phase 3 trials of elenbecestat show no harm to cognition, leaving open a chance that the drugs could be used safely in the future.
The first whole-genome manipulation of protein expression in neurons by CRISPR reveals a deadly chain of events. Bad processing by lysosomes leads to build-up of lipids and iron. Oxidative stress revs up. Neurons die by ferroptosis.
African Americans are likelier than non-Hispanic Caucasians to carry low-expression TREM2 variants, and less likely to carry a high-expression variant. As a result, they have less soluble TREM2 in their cerebrospinal fluid.
By shifting to home nursing and telemedicine, clinical researchers kept inching ahead during lockdowns.
At AD/PD 2021, clinicians discussed neurological symptoms and brain tissue damage in older people who died from COVID-19.
In the negative Phase 2 trial of prasinezumab, populations with more rapid decline benefited; this informed the design of a new Phase 2b study.
Both shy and funny, Allsop was a pioneer of modern Alzheimer's research.